Mara Goldstein analyst MIZUHO

Currently out of the existing stock ratings of Mara Goldstein, 133 are a BUY (74.72%), 43 are a HOLD (24.16%), 2 are a SELL (1.12%).

Mara Goldstein

Work Performance Price Targets & Ratings Chart

Analyst Mara Goldstein, currently employed at MIZUHO, carries an average stock price target met ratio of 48.17% that have a potential upside of 45.66% achieved within 279 days.

Mara Goldstein’s has documented 339 price targets and ratings displayed on 39 stocks. The coverage is on Healthcare, Communication Services sectors.

Most recent stock forecast was given on INCY, yte at 04-Nov-2025.

Wall Street Analyst Mara Goldstein

Analyst best performing recommendations are on FTSV (FORTY SEVEN).
The best stock recommendation documented was for CRVS (CORVUS PHARMACEUTICALS) at 3/30/2023. The price target of $3.5 was fulfilled within 69 days with a profit of $2.71 (343.04%) receiving and performance score of 49.72.

Average potential price target upside

CELG Celgene CLDX Celldex Therapeutics CRVS Corvus Pharmaceuticals CTMX CytomX Therapeutics FATE Fate Therapeutics FTSV Forty Seven IMGN ImmunoGen INCY yte KDMN Kadmon Holdings MRK Merck mpany NLNK NewLink Genetics RDUS Schnitzer Steel Industries RLYP Relypsa TC TuanChe ADR AGTC Applied Genetic IOVA Iovance Biotherapeutics RCUS Arcus Biosciences SNSS Sunesis Pharmaceuticals EFTR Effector Therapeutics LUMO Lumos Pharma NKTR Nektar Therapeutics SGEN Seagen LPTX Leap Therapeutics ADAP Adaptimmune Therapeutics Plc NLTX Neoleukin Therapeutics ARDX Ardelyx AUTL Autolus Therapeutics Ltd ERAS Erasca IMRX Immuneering Corp TCRR Tcr2 Therapeutics VSTM Verastem XNCR Xencor INAB In8bio  CYTK Cytokinetics GNCA Genocea Biosciences KPTI Karyopharm Therapeutics KURA Kura Oncology RXDX Prometheus Biosciences SLRX Salarius Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 01-Nov-2019

$101

$-7.24 (-6.69%)

$101

6 years 4 months 15 days ago
(01-Nov-2019)

2/8 (25%)

$-7.53 (-6.94%)

171

Hold Since 26-Oct-2018

$115

$6.76 (6.25%)

$102

6 years 4 months 15 days ago
(01-Nov-2019)

3/12 (25%)

$6.47 (5.96%)

382

Hold Since 01-Nov-2019

$102

6 years 4 months 15 days ago
(01-Nov-2019)

1/1 (100%)

$18.78 (22.57%)

322

Hold Since 19-Aug-2019

$100

$-8.24 (-7.61%)

$128

6 years 6 months 25 days ago
(19-Aug-2019)

3/6 (50%)

$4.78 (5.02%)

159

Buy Since 13-Feb-2018

$102

$-6.24 (-5.76%)

$105

6 years 10 months 13 days ago
(03-May-2019)

4/4 (100%)

$5.12 (5.28%)

207

Show more analysts

Please expand the browser size to see the chart

Which stock is Mara Goldstein is most bullish on?

Potential upside of $25.03 has been obtained for RCUS (ARCUS BIOSCIENCES)

Which stock is Mara Goldstein is most reserved on?

Potential downside of -$2.54 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Mara Goldstein?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?